Lupin Limited has announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of Sugammadex Injection, reinforcing its presence in the U.S. hospital injectable market. Sugammadex is a selective neuromuscular blockade reversal agent used to rapidly reverse the effects of rocuronium bromide and vecuronium bromide during surgical procedures. The approval follows the company’s earlier tentative approval and enables commercial availability in the United States.
Lupin’s Sugammadex Injection is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials. The product has been approved through an Abbreviated New Drug Application (ANDA) and is bioequivalent to Merck’s Bridion® Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery. The approval confirms that Lupin’s generic formulation meets the FDA’s standards for quality, safety, and therapeutic equivalence.
The commercial launch strengthens Lupin’s injectable anesthesia portfolio while enhancing access to a cost-effective generic alternative for hospitals and surgical centers across the United States. Sugammadex has become an important component of modern perioperative care because of its ability to provide rapid and predictable reversal of neuromuscular blockade, facilitating timely patient recovery and improving operating room efficiency. Availability of a generic formulation may contribute to broader adoption while helping reduce healthcare costs associated with surgical care. The approval also reflects Lupin’s continued focus on expanding its complex injectable portfolio and increasing its footprint in the U.S. institutional healthcare market.
The U.S. FDA approval and launch of Sugammadex Injection represent another significant regulatory and commercial milestone for Lupin. By introducing a generic equivalent of Bridion®, the company expands access to an essential perioperative medicine while reinforcing its strategy of delivering high-quality, affordable injectable therapies to healthcare providers in the United States.
